Market Cap 594.57M
Revenue (ttm) 283.47M
Net Income (ttm) -42.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15.07%
Debt to Equity Ratio 0.00
Volume 408,800
Avg Vol 330,400
Day's Range N/A - N/A
Shares Out 30.44M
Stochastic %K 1%
Beta 1.06
Analysts Sell
Price Target $22.67

Company Profile

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer serv...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 626 350 0537
Fax: 626 454 1667
Address:
4399 Santa Anita Avenue, El Monte, United States
AlexBo6
AlexBo6 Jun. 21 at 11:27 AM
$FLGT #Bullish , hell yeh..
0 · Reply
Sexydream
Sexydream Jun. 20 at 3:51 PM
$FLGT 19s are here. 17s coming soon folks. Will fill the 17.50 gap.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 17 at 12:25 PM
$FLGT Fulgent not mentioned here but it is a huge potential market. Not sure how much or when the newer ADC targeted drugs will also be used though. https://www.globenewswire.com/news-release/2025/03/27/3050697/28124/en/The-Global-Market-for-Paclitaxel-Injections-Presents-an-11-17-Billion-Revenue-Opportunity-by-2029-Analysis-of-Key-Players-Pfizer-BMS-Fresenius-Kabi-Oncology-Abbott-Labs-and-Viatris.html
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:50 PM
$FLGT The last thing I will say is that, yes, as the guys imply below, canceling the forward agreement does feel bullish. We will see.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:41 PM
$FLGT I wish Ming never entered into those forward agreements in the first place. Because he perhaps knew the likely future sequence of events regarding the fold-in of Pharma, and its eventual downward effect on the stock price. In my opinion, while legal, it just felt a bit like a conflict of interest. And calling his trust the ‘Dynasty Trust’ seems a little overbearing too.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:30 PM
$FLGT In Nov 2022, Fulgent paid to bring Pharma back into Fulgent Genetics. Remember that Ming had another agreement earlier, in June 2022 where his Trust received $44M for pledging 1M shares. Maybe ‘fleeced’ is the wrong word but Ming did ‘win’ vs. the bank.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:20 PM
$FLGT What you guys are missing is that Ming’s trust received $29M up front in cash from the bank in creating that Sep 2022 agreement. Ming totally fleeced the bank by canceling the agreement now for just $16.4M.
1 · Reply
jf152
jf152 Jun. 13 at 8:21 PM
$FLGT $16,446,960.00 was paid to cancel this contract.
0 · Reply
CrayP
CrayP Jun. 13 at 11:23 AM
$FLGT Not for nothing the settlement of Ming's forward variable contract was always a risk and overhang, but he cancelled the contract and settled in cash instead of 800K shares.
1 · Reply
Sexydream
Sexydream Jun. 12 at 8:07 PM
$FLGT hope you all enjoyed this colossal run to 21. LOL. Watch it come down now. 👍
1 · Reply
Latest News on FLGT
Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

May 2, 2025, 12:27 PM EDT - 7 weeks ago

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript


Fulgent Reports First Quarter 2025 Financial Results

May 2, 2025, 7:00 AM EDT - 7 weeks ago

Fulgent Reports First Quarter 2025 Financial Results


Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 2:07 AM EST - 8 months ago

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript


Fulgent Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 8 months ago

Fulgent Reports Third Quarter 2024 Financial Results


Fulgent to Participate in Upcoming Conferences

Nov 5, 2024, 8:00 AM EST - 8 months ago

Fulgent to Participate in Upcoming Conferences


Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Sep 25, 2024, 11:32 AM EDT - 9 months ago

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential


Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 10:24 AM EDT - 11 months ago

Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript


Fulgent Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 11 months ago

Fulgent Reports Second Quarter 2024 Financial Results


Fulgent Genetics: Growth Is Returning

Jun 6, 2024, 11:36 AM EDT - 1 year ago

Fulgent Genetics: Growth Is Returning


Fulgent Reports First Quarter 2024 Financial Results

May 3, 2024, 7:00 AM EDT - 1 year ago

Fulgent Reports First Quarter 2024 Financial Results


Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 10:59 AM EST - 1 year ago

Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript


Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21, 2024, 7:20 AM EST - 1 year ago

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value


AlexBo6
AlexBo6 Jun. 21 at 11:27 AM
$FLGT #Bullish , hell yeh..
0 · Reply
Sexydream
Sexydream Jun. 20 at 3:51 PM
$FLGT 19s are here. 17s coming soon folks. Will fill the 17.50 gap.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 17 at 12:25 PM
$FLGT Fulgent not mentioned here but it is a huge potential market. Not sure how much or when the newer ADC targeted drugs will also be used though. https://www.globenewswire.com/news-release/2025/03/27/3050697/28124/en/The-Global-Market-for-Paclitaxel-Injections-Presents-an-11-17-Billion-Revenue-Opportunity-by-2029-Analysis-of-Key-Players-Pfizer-BMS-Fresenius-Kabi-Oncology-Abbott-Labs-and-Viatris.html
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:50 PM
$FLGT The last thing I will say is that, yes, as the guys imply below, canceling the forward agreement does feel bullish. We will see.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:41 PM
$FLGT I wish Ming never entered into those forward agreements in the first place. Because he perhaps knew the likely future sequence of events regarding the fold-in of Pharma, and its eventual downward effect on the stock price. In my opinion, while legal, it just felt a bit like a conflict of interest. And calling his trust the ‘Dynasty Trust’ seems a little overbearing too.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:30 PM
$FLGT In Nov 2022, Fulgent paid to bring Pharma back into Fulgent Genetics. Remember that Ming had another agreement earlier, in June 2022 where his Trust received $44M for pledging 1M shares. Maybe ‘fleeced’ is the wrong word but Ming did ‘win’ vs. the bank.
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 16 at 5:20 PM
$FLGT What you guys are missing is that Ming’s trust received $29M up front in cash from the bank in creating that Sep 2022 agreement. Ming totally fleeced the bank by canceling the agreement now for just $16.4M.
1 · Reply
jf152
jf152 Jun. 13 at 8:21 PM
$FLGT $16,446,960.00 was paid to cancel this contract.
0 · Reply
CrayP
CrayP Jun. 13 at 11:23 AM
$FLGT Not for nothing the settlement of Ming's forward variable contract was always a risk and overhang, but he cancelled the contract and settled in cash instead of 800K shares.
1 · Reply
Sexydream
Sexydream Jun. 12 at 8:07 PM
$FLGT hope you all enjoyed this colossal run to 21. LOL. Watch it come down now. 👍
1 · Reply
blahblahg
blahblahg Jun. 11 at 5:54 PM
$FLGT Hey folks, I recently wrote this intro on Fulgent Genetics for my Substack newsletter, please hit the subscribe button if you enjoy, and feel free to check out my other articles. https://unfairvalue.substack.com/p/fulgent-genetics-cash-rich-and-underappreciated?r=2ra1p4
0 · Reply
jf152
jf152 Jun. 10 at 1:48 PM
0 · Reply
Chairman5
Chairman5 Jun. 10 at 12:46 AM
$FLGT looks like straight to 30s
1 · Reply
theshortsqueezer2022
theshortsqueezer2022 Jun. 8 at 3:18 AM
$FLGT good job bulls. This is now heading to triple digits.
0 · Reply
Jerseyman2222000
Jerseyman2222000 Jun. 8 at 1:53 AM
$FLGT Hello Fulgent friends. I’ll be purchasing 500,000 shares in the next week or so. I hope everyone has been well.
1 · Reply
jf152
jf152 Jun. 6 at 9:18 PM
$FLGT Up 9.36% since this completely unjustified prediction @Sexydream
0 · Reply
jf152
jf152 Jun. 3 at 9:00 PM
$FLGT What gaps are being filled?
0 · Reply
jf152
jf152 Jun. 3 at 8:58 PM
0 · Reply
ClarityOfPurpose
ClarityOfPurpose Jun. 3 at 4:02 PM
$FLGT If FID-007 fails, they could close the pharma division and then their share price should rise due to ending the negative EV that is based on current pharma cash burn. If FID-007 succeeds, the share price should rise. Win-Win!
0 · Reply
bdubs84
bdubs84 Jun. 2 at 5:26 PM
$FLGT a couple things 1)their readout must not be great on FID-007 since no ASCO and 2) stock price will likely be hurt by this, so when they release this info in June PR, they commit to a significant share buyback program…)200M at $25 (won’t be able to buy all at $20 when they announce it) is 8 million shares, and assuming same market cap, that would equate to a share price of $33. Market will start pricing this in making all those July calls and longer dated Oct/Jan call print. Longer term, someone likely steps in and buys this.
1 · Reply
RangerYun
RangerYun Jun. 1 at 4:01 PM
$FLGT odd that 2024 they presented at ASCO. but not this year. FID 007 is due for an update - in Feb 25 ER call, CEO said update is likely at ASCO. but in May ER call, he did not mention ASCO. but update data is due nonetheless
1 · Reply
jf152
jf152 May. 29 at 10:27 PM
$FLGT @RangerYun
4 · Reply